🇺🇸

US SEC Filing Intelligence

· daily

USA Insider Trading Pulse — September 03, 2026

The September 3, 2026, insider trading filings reveal a market characterized by cautious optimism and strategic positioning. The most significant signal is a substantial open-market purchase by the Chairman & CEO of Amrize Ltd, totaling ~$638K, indicating strong management conviction. This is contrasted by notable insider selling at EUROSEAS LTD., Borr Drilling Ltd, CORVEL CORP, and APTARGROUP, suggesting sector-specific headwinds. A wave of equity awards across companies like STRATTEC SECURITY, HONDA MOTOR, and NOVAGOLD RESOURCES indicates standard compensation practices, while tax-withholding sales at HMH Holding and Yum China are routine events. The CEO of 17 Education & Technology Group continued to accumulate shares, reinforcing a bullish stance on the company's turnaround. Overall, the data points to a bifurcated market where insiders are voting with their wallets, favoring select value and turnaround stories while reducing exposure to cyclical and potentially overvalued sectors.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 03, 2026

Today's digest captures a surge in SPAC activity, with 8 of 16 filings involving blank-check companies pursuing or finalizing business combinations, signaling robust deal-making in the de-SPAC pipeline. A key cross-cutting theme is the aggressive use of non-redemption agreements and dilutive financing structures (e.g., Ribbon Acquisition Corp.) to secure trust funds and extend deadlines, highlighting persistent redemption pressure. On the operational M&A front, Hillman Solutions and HF Foods Group closed strategic bolt-on acquisitions, expanding into new markets (industrial fasteners and Canada, respectively), while NET Power advanced its Project Permian. The PlusAI merger stands out as the highest-value deal at an $800M pre-money valuation, though it remains pre-commercial. No significant period-over-period financial trends (e.g., revenue growth, margin compression) were available from the filings, as most are SPAC-related and lack operational history. The most critical development is the high approval rate (90.3%) for the GOWell Technology merger, suggesting strong shareholder alignment, contrasted by the multiple extension attempts by Andretti Acquisition Corp. II, indicating deal execution risk.

16 high priority 16 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 03, 2026

This overnight filing cycle is dominated by a surge in SPAC activity, with four major business combination announcements (PlusAI, Remix Therapeutics, Ursa Major, Elroy Air) signaling a potential resurgence in the de-SPAC market. A significant capital allocation theme emerges from large-scale share repurchase programs at Toyota (JPY 1 trillion) and ORIX (¥250 billion), indicating strong corporate confidence in undervaluation. The biotech sector presents a stark contrast, with Passage BIO's cash-burning pre-revenue status and a major licensing deal between HUTCHMED and GSK, highlighting the sector's binary risk/reward profile. Insider selling is concentrated in the technology sector, with multiple executives at Rackspace Technology and RxSight reducing their holdings, which warrants caution. A notable related-party acquisition by Scienjoy Holding and a highly dilutive financing structure for Ribbon Acquisition Corp. present complex risk/reward scenarios for investors.

27 high priority 23 medium 50 total filings
· daily

Biotech Small-Cap Approvals — September 02, 2026

This digest covers 11 FDA approvals from a single day (September 2, 2026), all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion) with a mix of 3 bullish and 8 neutral signals. The period is dominated by generic/biosimilar-style approvals for established molecules (POMALIDOMIDE, FINERENONE, HYDROCORTISONE, EMTRICITABINE) from sponsors like CIPLA, SANDOZ, APOTEX, and NATCO, signaling continued commoditization pressure in small-molecule and specialty generics. The highest-conviction signals are two NME approvals with Priority Review and Orphan designations: DARAXONRASIB (RASONQUE) from REVOLUTION MEDICINES INC and an undisclosed NME from PRIOVANT THERAPEUTICS INC, both representing high-value, targeted oncology/rare disease opportunities with significant commercial upside. Key risks include the lack of disclosed commercial data (peak sales, pricing, exclusivity) for all approvals, and the potential for IRA negotiation exposure for any small-molecule NMEs that achieve blockbuster status.

11 total filings
· daily

NME Blockbuster Approvals — September 02, 2026

In the period from August 26 to August 28, 2026, the FDA approved three New Molecular Entities (NMEs) under Priority Review and Orphan Drug designations, all flagged as bullish signals with high materiality. The approvals span Takeda Pharmaceuticals’ RUSFERTIDE ACETATE (MIMRYLO), an undisclosed NME from Priovant Therapeutics, and Revolution Medicines’ DARAXONRASIB (RASONQUE). While no specific therapeutic area clustering is confirmed due to limited data, the concentration of NMEs with Orphan and Priority Review status signals a strong regulatory tailwind for targeted, high-unmet-need therapies. The highest-conviction signal is DARAXONRASIB from Revolution Medicines, given its potential in RAS-mutant cancers—a historically difficult target—and the sponsor’s focused oncology pipeline. A key risk is the lack of disclosed peak sales estimates, pricing power, or exclusivity details, limiting near-term commercial valuation assessments.

3 total filings
· daily

Big Pharma Approvals — September 02, 2026

The September 2, 2026, FDA approval stream for Big Pharma sponsors delivered 8 approvals, all classified as 'Other' (no NMEs, biosimilars, or label expansions per the provided mix), yet all 8 carry bullish signals. The dominant theme is HIV and metabolic franchise expansion, with Gilead Sciences receiving four label expansions (lenacapavir, bictegravir/lenacapavir, and one undisclosed) and Eli Lilly receiving two for tirzepatide (Mounjaro), while Takeda's rusfertide acetate (Mimrylo) stands out as the highest-conviction signal—an NME with Priority Review and Orphan designation, indicating strong unmet need in a rare disease. Janssen's ustekinumab (Stelara) label expansion adds to the bullish mix. Key watch items include the lack of disclosed commercial data (peak sales, exclusivity, pricing) and the potential for IRA negotiation exposure on small molecules like tirzepatide and bictegravir/lenacapavir, which could pressure long-term revenue. Overall, the period signals robust franchise management and pipeline execution across major sponsors, but investors should seek clarity on the specific indications and commercial potential behind these approvals.

8 total filings
· daily

Orphan Drug Approvals — September 02, 2026

During the period of September 2, 2026, the FDA approved four orphan-designated drugs, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion), generating four bullish signals. The dominant theme is a high-conviction oncology and precision medicine cluster, with two NME approvals (RUSFERTIDE ACETATE from Takeda and DARAXONRASIB from Revolution Medicines) receiving Priority Review and Orphan Drug status, signaling strong unmet need and premium pricing potential. The highest-conviction signal is DARAXONRASIB (RASONQUE) from Revolution Medicines, a targeted RAS inhibitor with breakthrough potential in KRAS-mutant cancers, supported by Priority Review and Orphan designations. A key risk is the lack of disclosed commercial data (peak sales, pricing, exclusivity) for all four drugs, creating uncertainty in revenue forecasting and market positioning.

4 total filings
· daily

New Drug Approvals (Original) — September 02, 2026

The September 2, 2026 FDA approval stream featured 14 approvals, all classified as 'Other' (no NME, biosimilar, or label expansion designations in the provided data, though several approvals carry NME, biosimilar, or label expansion characteristics). The period was dominated by biosimilar and generic-type approvals, with notable NME approvals for Takeda's RUSFERTIDE ACETATE (MIMRYLO), Priovant's undisclosed NME, and Revolution Medicines' DARAXONRASIB (RASONQUE), all with Priority Review and Orphan designations. The highest-conviction signal is DARAXONRASIB, a targeted oncology therapy for KRAS-mutant cancers, which could be a significant commercial opportunity for Revolution Medicines. Key risks include the lack of commercial data (sales estimates, pricing) across all approvals, and the potential for biosimilar competition to erode originator revenues for drugs like POMALIDOMIDE, FINERENONE, and EMTRICITABINE. Investors should monitor launch execution and payer coverage for the NMEs, as well as the competitive impact of biosimilars on existing franchises.

14 total filings
· daily

VA Healthcare & Services Contracts — September 02, 2026

Over a single-day period, the Department of Veterans Affairs awarded one contract totaling $143.6 million to Oracle Health Government Services, Inc. for data migration services under the VA’s Electronic Health Record Modernization (OEHRM) program. This is a purely civilian award with no defense exposure, reflecting the VA’s continued investment in IT modernization. The contract is a firm-fixed-price, non-competitive delivery order with a performance period that ended in November 2021, meaning it has no current revenue relevance. The highest-conviction signal is neutral: the sole-source relationship suggests Oracle’s entrenched position, but the expired contract and lack of competition data limit actionable investment implications. Key risk is the absence of any re-compete or follow-on award data, leaving Oracle’s competitive moat unconfirmed for future VA IT contracts.

1 total filings
· daily

New Federal Contractors — September 02, 2026

This digest covers three federal contracts totaling $633.7 million, all awarded to civilian agencies with zero defense-related exposure, signaling a pure civilian-sector procurement theme. The dominant award is a $365.4 million cost-plus delivery order to Booz Allen Hamilton from the GSA for IT systems design, representing 58% of total obligation and carrying moderate execution risk due to 167 subawards. A $143.6 million sole-source VA data migration contract to Oracle Health Government Services is likely completed, offering limited current revenue relevance. The $124.7 million NASA modification to Vertex Aerospace lacks detail, reducing conviction. Key risk: Booz Allen's contract nears expiration in April 2024, creating recompetition uncertainty. Highest-conviction signal is neutral, with no bullish or bearish extremes across the set.

3 total filings
· daily

Significant Contract Modifications ($10M+) — September 02, 2026

This digest covers three significant contract modifications totaling $633.7 million, all from civilian agencies with zero defense-related awards, signaling a clear civilian-sector focus for the period. The dominant theme is federal IT modernization, led by a $365.4 million Booz Allen Hamilton cost-plus award from GSA for IT systems design, which represents the highest-conviction signal due to its size and ongoing federal priorities. However, the Booz Allen contract's negative outlayed amount and heavy subaward reliance introduce execution and margin risks, while the $143.6 million Oracle Health VA contract is largely historical (completed in 2021) and offers limited current relevance. The $124.7 million Vertex Aerospace NASA modification lacks sufficient detail for actionable analysis, but the aggregate neutral signal strength (5.3/10) and lack of bullish or bearish signals suggest a stable but unexciting investment landscape for government services contractors.

3 total filings
· daily

Contract Deobligations Alert — September 02, 2026

The three contracts analyzed represent $633.7 million in total obligations, all from civilian agencies (GSA, VA, NASA), with zero defense-related awards. The dominant theme is federal IT modernization, led by Booz Allen Hamilton's $365.4 million GSA delivery order for IT systems design, which carries the highest materiality (7/10) but shows a negative outlayed amount, signaling potential de-obligation risk. Oracle Health's $143.6 million VA data migration contract is likely completed, offering limited current relevance, while Vertex Aerospace's $124.7 million NASA modification lacks detail. The highest-conviction signal is the continued civilian IT spending, though execution risks and lack of defense exposure temper enthusiasm. Key watch items include Booz Allen's contract recompetition and resolution of its negative outlay.

3 total filings
· daily

Contract Option Exercises — September 02, 2026

The September 2, 2026 option exercise stream totals $633.7 million in obligations, all from civilian agencies (GSA, VA, NASA), with no defense-related awards. The dominant theme is federal IT modernization, led by Booz Allen Hamilton's $365.4 million GSA IT systems design delivery order, which represents the highest-conviction signal (materiality 7/10) but carries execution risk due to heavy subaward reliance and a negative outlayed amount. Oracle Health's $143.6 million VA data migration order is likely completed, limiting current relevance, while Vertex Aerospace's $124.7 million NASA modification lacks detail. Key risks include potential de-obligation on the Booz Allen contract and recompetition pressure as its April 2024 end date approaches. Overall, the stream is neutral, with no bullish or bearish signals, reflecting mature, non-transformative contract actions.

3 total filings
· daily

Federal IT & Cybersecurity Contracts — September 02, 2026

The two contracts analyzed total $509,049,971 in obligations, both from civilian agencies (GSA and VA), with zero defense-related awards. The dominant theme is federal IT modernization, with Booz Allen Hamilton's $365.4M GSA delivery order for IT systems design representing the highest materiality and a stable revenue stream through April 2024, though execution risk is elevated by heavy subaward reliance and a negative outlayed amount. Oracle Health's $143.6M VA data migration task order, awarded non-competitively, signals a sole-source relationship but is likely completed, limiting current investment relevance. The highest-conviction signal is Booz Allen's cost-plus pricing structure, which reduces profit volatility but caps upside, while the key risk is the unresolved negative outlayed amount that may indicate de-obligation trends. Investors should monitor Booz Allen's contract modifications and recompetition announcements as the contract nears expiration, and track VA's future health IT procurements for Oracle's competitive positioning.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — September 02, 2026

The three contracts reviewed total $633.7 million, all civilian, with zero defense exposure—underscoring a pure civilian-agency theme. The highest-conviction signal is Booz Allen Hamilton's $365.4 million GSA award for IT systems design, which represents its largest single contract in this digest but carries execution risk from $113.6 million in subawards and a cost-plus structure limiting margin upside. Oracle Health’s $143.6 million VA data migration contract is non-competitive and likely expired, offering no current revenue visibility. Vertex Aerospace’s $124.7 million NASA modification lacks detailed data, reducing actionable insight. The key risk is that the Booz Allen award's negative outlayed amount could signal de-obligation trends, warranting close monitoring for margin compression or recompetition threats. Overall, the digest reveals moderate, near-term civilian IT spend but no transformative growth catalysts.

3 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 02, 2026

The 13 filings for the S&P 500 Technology stream reveal a sector bifurcated by AI investment. Broadcom's record Q3 FY2026 results, with revenue surging 86% YoY and AI semiconductor revenue up 221% YoY, underscore the massive demand for AI infrastructure. However, a wave of high-profile insider selling—including NVIDIA Director Stevens ($98.5M), Microsoft CEO Nadella ($16.5M), and Synopsys' Executive Chair ($11M)—signals potential caution at the top. Cisco's mixed fiscal 2026 results show solid revenue growth of 12% YoY but are tempered by a 0.4-point gross margin decline and inventories doubling, hinting at supply chain pressures. Microsoft's segment restructuring into 'Agents and Infra' and 'Devices and Consumer' for FY2027 is a strategic pivot to capture the AI agent era. The dominant theme is that while AI-fueled growth is explosive, insiders are taking profits, and legacy hardware players face margin and inventory headwinds.

11 high priority 2 medium 13 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 02, 2026

The 18 filings from NASDAQ-100 constituents reveal a powerful bifurcation between AI-driven growth and legacy business challenges. Broadcom's record Q3 FY2026 results, with revenue surging 86% YoY and AI semiconductor revenue up 221%, underscore the massive capital reallocation toward AI infrastructure. However, Cisco's mixed fiscal 2026 results, with a 0.4-point gross margin decline and inventories doubling, highlight supply chain and demand headwinds in networking. Insider activity is a key theme: heavy selling by top executives at Microsoft (CEO Satya Nadella sold ~$16.5M), NVIDIA (Director Mark Stevens sold ~$98.5M), and Gilead Sciences (CEO Daniel O'Day sold ~$1.19M) signals potential valuation concerns or profit-taking at elevated levels. Meanwhile, Netflix's board-wide option awards (9 directors and the CAO receiving ~774-902 options each) suggest a retention-focused compensation strategy. A critical portfolio-level pattern is the divergence in capital allocation: Broadcom is generating massive free cash flow ($13.7B, 46% of revenue) while Cisco's operating cash flow is flat, and Microsoft is restructuring its reporting segments to emphasize AI. The most actionable insight is the contrast between Broadcom's accelerating AI momentum and the insider selling at NVIDIA and Microsoft, which may indicate a sector rotation within tech.

6 high priority 12 medium 18 total filings
· daily

High-Value Federal Grants ($5M+) — September 02, 2026

The three contracts analyzed total $633.7 million in obligations, all from civilian agencies (0% defense-related), signaling continued federal investment in IT modernization and data migration outside the defense sector. The dominant theme is civilian IT services, led by a $365.4 million GSA award to Booz Allen Hamilton for IT systems design, followed by a $143.6 million VA task order to Oracle Health Government Services for data migration, and a $124.7 million NASA modification to Vertex Aerospace. The highest-conviction signal is Booz Allen's substantial revenue stream, though execution risk from heavy subaward reliance and a negative outlayed amount warrant caution. Key risks include potential de-obligation trends and the expiration of Booz Allen's contract in April 2024, which could trigger a recompetition. Overall, the digest reflects stable civilian IT spending but limited transformative upside, with no defense exposure in this period.

3 total filings